Experience

AviadoBio Announces Exclusive Option and License Agreement With Astellas

October 11, 2024

Cooley advised AviadoBio, a company focused on gene therapy for neurodegenerative disorders, on its exclusive option and license agreement with Astellas Pharma for AVB-101, an investigational, adeno-associated virus (AAV)-based gene therapy in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations (FTD-GRN).

Read more

Related contacts

Frances Stocks Allen
Partner, London
Alan W. Tamarelli
Partner, New York
Tom Goodman
Partner, London
Joe Sandys
Special Counsel, London
Mark Jones
Associate, London

Related Practices & Industries

EyeBiotech Limited Announces $130 Million Series A

November 14, 2023

Cooley advised EyeBiotech Limited, a privately held, clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, on the close of an extension to its Series A financing, bringing the total raised to date to $130 million.

Related contacts

Tom Goodman
Partner, London
Dr. Michael Tuscan
Partner, Washington, DC
Christian Plaza
Partner, Reston
Karen Tsai
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC
Dr. Bonnie Weiss McLeod
Of Counsel, Washington, DC
Ellen Dewhurst
Associate, London

Related Practices & Industries

Cooley Advises Quell Therapeutics on its Exclusive Treg Collaboration With AstraZeneca

June 9, 2023

Cooley advised Quell Therapeutics, a leading T-regulatory (Treg) cell therapy biotech company based in London, on its exclusive collaboration with AstraZeneca.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Frances Stocks Allen
Partner, London
Tom Goodman
Partner, London
Jiqiang Lin
Associate, New York
J. Brian Stalter
Special Counsel, New York
Ellen Dewhurst
Associate, London

Related Practices & Industries

Exscientia – $510.4 Million IPO

October 6, 2021

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Read more

Related contacts

Claire Keast-Butler
Co-Partner in Charge – London, London
Div Gupta
Partner, New York
Marc Recht
Partner, Boston
David Wilson
Partner, London
Chris Stack
Partner, London
Nicola Squire
Partner, London
Jack Jones
Special Counsel, London
Tom Goodman
Partner, London
Paula Holland
Partner, London
Aaron Pomeroy
Partner, Colorado
Calvin Lee
Associate, New York
Courtney Thorne
Partner, London

Related Practices & Industries

Exscientia Inks Investment of up to $525 Million

May 10, 2021

Cooley advised Exscientia, a clinical-stage pharmatech company, on its $225 million Series D funding round led by SoftBank Vision Fund 2, which is also providing an additional $300 million equity commitment that can be drawn at Exscientia’s discretion. Lawyers Claire Keast-Butler and Tom Goodman led the Cooley team advising Exscientia.

Read more

Related contacts

Claire Keast-Butler
Co-Partner in Charge – London, London
Tom Goodman
Partner, London
Paula Holland
Partner, London
Marc Recht
Partner, Boston

Related Practices & Industries

View more

Rankings and accolades

The Legal 500 UK: Venture Capital (2022)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.